WO2010142456A1 - Solid compositions comprising 5-aminolevulinic acid - Google Patents

Solid compositions comprising 5-aminolevulinic acid Download PDF

Info

Publication number
WO2010142456A1
WO2010142456A1 PCT/EP2010/003531 EP2010003531W WO2010142456A1 WO 2010142456 A1 WO2010142456 A1 WO 2010142456A1 EP 2010003531 W EP2010003531 W EP 2010003531W WO 2010142456 A1 WO2010142456 A1 WO 2010142456A1
Authority
WO
WIPO (PCT)
Prior art keywords
ala
pharmaceutical product
solid
solid pharmaceutical
triglycerides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/003531
Other languages
English (en)
French (fr)
Inventor
Oddveig Sellaeg Helland
Gry Stensrud
Bjorn Klem
Jon Erik Braenden
Aslak Godal
Jo Klaveness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42628133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010142456(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2763837A priority Critical patent/CA2763837A1/en
Priority to NZ596946A priority patent/NZ596946A/en
Priority to CN2010800256075A priority patent/CN102802612A/zh
Priority to US13/377,692 priority patent/US20120134921A1/en
Priority to BRPI1011650A priority patent/BRPI1011650A2/pt
Priority to JP2012514392A priority patent/JP2012529451A/ja
Priority to SG2011090040A priority patent/SG176687A1/en
Application filed by Photocure ASA filed Critical Photocure ASA
Priority to AU2010257752A priority patent/AU2010257752B2/en
Priority to KR1020117030694A priority patent/KR20140014401A/ko
Priority to RU2011150920/15A priority patent/RU2527328C2/ru
Priority to EP10725043A priority patent/EP2440188A1/en
Priority to MX2011013069A priority patent/MX2011013069A/es
Publication of WO2010142456A1 publication Critical patent/WO2010142456A1/en
Priority to ZA2011/08850A priority patent/ZA201108850B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the solid pharmaceutical products according to the invention are for use in photodynamic diagnosis of cancer and pre-cancerous conditions in the lower gastrointestinal tract, preferably in the colon and rectum.
  • non-ionic emulsifiers are fatty alcohols and/or ethoxylated fatty alcohols like cetostearyl alcohol or cetomacrogol.
  • the solid pharmaceutical product further comprises d) optionally one or more mucoadhesives e) optionally one or more pharmaceutically acceptable excipients other than b), and c); f) optionally one or more surface penetration agents; and g) optionally one or more chelating agents.
  • the solid triglycerides have a melting point of below or at the body temperature of the human or non-human animal the capsule is administered to.
  • the capsule is administered to a human and the melting point of said solid triglycerides is between about 26 0 C and 37 0 C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2010/003531 2009-06-11 2010-06-11 Solid compositions comprising 5-aminolevulinic acid Ceased WO2010142456A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MX2011013069A MX2011013069A (es) 2009-06-11 2010-06-11 Composiciones solidas que comprenden acido 5-aminolevulinico.
AU2010257752A AU2010257752B2 (en) 2009-06-11 2010-06-11 Solid compositions comprising 5-aminolevulinic acid
CN2010800256075A CN102802612A (zh) 2009-06-11 2010-06-11 含有5-氨基酮戊酸的固态组合物
US13/377,692 US20120134921A1 (en) 2009-06-11 2010-06-11 Solid compositions comprising 5-aminolevulinic acid
BRPI1011650A BRPI1011650A2 (pt) 2009-06-11 2010-06-11 composições sólidas compreendendo ácido 5-aminolevulínico
JP2012514392A JP2012529451A (ja) 2009-06-11 2010-06-11 ５−アミノレブリン酸を含む固体組成物
SG2011090040A SG176687A1 (en) 2009-06-11 2010-06-11 Solid compositions comprising 5-aminolevulinic acid
CA2763837A CA2763837A1 (en) 2009-06-11 2010-06-11 Solid compositions comprising 5-aminolevulinic acid
RU2011150920/15A RU2527328C2 (ru) 2009-06-11 2010-06-11 Твердые композиции, содержащие 5-аминолевулиновую кислоту
NZ596946A NZ596946A (en) 2009-06-11 2010-06-11 Solid compositions comprising 5-aminolevulinic acid
KR1020117030694A KR20140014401A (ko) 2009-06-11 2010-06-11 5-아미노레불린산을 포함하는 고체 조성물
EP10725043A EP2440188A1 (en) 2009-06-11 2010-06-11 Solid compositions comprising 5-aminolevulinic acid
ZA2011/08850A ZA201108850B (en) 2009-06-11 2011-12-01 Solid compositions comprising 5-aminolevulinic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09251538.6 2009-06-11
EP09251538 2009-06-11

Publications (1)

Publication Number Publication Date
WO2010142456A1 true WO2010142456A1 (en) 2010-12-16

Family

ID=42628133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/003531 Ceased WO2010142456A1 (en) 2009-06-11 2010-06-11 Solid compositions comprising 5-aminolevulinic acid

Country Status (18)

Country Link
US (1) US20120134921A1 (enExample)
EP (1) EP2440188A1 (enExample)
JP (1) JP2012529451A (enExample)
KR (1) KR20140014401A (enExample)
CN (1) CN102802612A (enExample)
AU (1) AU2010257752B2 (enExample)
BR (1) BRPI1011650A2 (enExample)
CA (1) CA2763837A1 (enExample)
CL (1) CL2011003115A1 (enExample)
CO (1) CO6480960A2 (enExample)
CR (1) CR20110649A (enExample)
MX (1) MX2011013069A (enExample)
NZ (1) NZ596946A (enExample)
PE (1) PE20120858A1 (enExample)
RU (1) RU2527328C2 (enExample)
SG (1) SG176687A1 (enExample)
WO (1) WO2010142456A1 (enExample)
ZA (1) ZA201108850B (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014001268A1 (de) * 2012-06-25 2014-01-03 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten freisetzung von wirkstoffen
WO2014079972A1 (en) 2012-11-23 2014-05-30 Photocure Asa Device for photodynamic treatment
US8992954B2 (en) 2010-03-01 2015-03-31 Photocure Asa Compositions comprising a derivative of 5-aminolevulinic acid
EP2968128A4 (en) * 2013-03-12 2016-11-16 Applied Biores Inc CHELATING COFFEE FOR IMPROVED DRUG DISPERSION
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
US9956426B2 (en) 2015-02-26 2018-05-01 Amol Punjabi Upconverting nanoparticles
US11235168B2 (en) 2015-12-17 2022-02-01 Photocure Asa Method of photodynamic therapy (PDT) for bladder cancer
US11565123B2 (en) 2015-12-18 2023-01-31 Photocure Asa Device for photodynamic treatment
US11633486B2 (en) 2017-04-17 2023-04-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140067024A1 (en) 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
JP6588193B2 (ja) * 2014-07-31 2019-10-09 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル製剤
US20170216146A1 (en) * 2014-07-31 2017-08-03 Capsugel Belgium Nv Capsule formulation
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
CN105481946B (zh) * 2015-12-18 2019-05-21 浙江工商大学 5-氨基酮戊酸与3-羟基吡啶-4-酮的缀合物及其制备法和用途
US10744212B2 (en) 2016-03-14 2020-08-18 General Electric Company Topical application of nerve labeling dyes for image-guided surgery
CN107434753A (zh) * 2017-07-26 2017-12-05 南京大学 5‑氨基乙酰丙酸及其衍生物的泡腾片及其制备方法
PH12020550124B1 (en) 2017-12-01 2024-05-24 Nat Ct Child Health & Dev Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034267A (en) * 1995-03-10 2000-03-07 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US20030125388A1 (en) * 2000-01-28 2003-07-03 Bruno Gander 5-Aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
US20080227757A1 (en) * 2005-04-26 2008-09-18 Christel Muller-Goymann Formulation for dermal application
WO2009074811A2 (en) * 2007-12-12 2009-06-18 Photocure Asa Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3181062B2 (ja) * 1991-01-31 2001-07-03 帝國製薬株式会社 下部消化管崩壊経口製剤
US6492420B2 (en) * 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
EP2127642A3 (en) * 1998-08-13 2010-02-24 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
EP1184038B1 (en) * 1999-06-09 2005-12-28 Mochida Pharmaceutical Co., Ltd. System for release in lower digestive tract
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7264629B2 (en) * 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
TW577606U (en) * 2001-11-20 2004-02-21 Carry Computer Eng Co Ltd Improved structure of all-in-one silicon disk
GB0609809D0 (en) * 2006-05-17 2006-06-28 Photocure Asa Product

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034267A (en) * 1995-03-10 2000-03-07 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US20030125388A1 (en) * 2000-01-28 2003-07-03 Bruno Gander 5-Aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
US20080227757A1 (en) * 2005-04-26 2008-09-18 Christel Muller-Goymann Formulation for dermal application
WO2009074811A2 (en) * 2007-12-12 2009-06-18 Photocure Asa Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
B. MAYINGER ET AL., ENDOSCOPY, vol. 40, 2008, pages 106 - 109
DONNELLY RYAN F ET AL: "Influence of formulation factors on PpIX production and photodynamic action of novel ALA-loaded microparticles.", BIOPHARMACEUTICS & DRUG DISPOSITION MAR 2009 LNKD- PUBMED:19226650, vol. 30, no. 2, March 2009 (2009-03-01), pages 55 - 70, XP002601528, ISSN: 1099-081X *
E. ENDLICHER ET AL., GASTROINTESTINAL ENDOSCOPY, vol. 60, no. 3, 2004, pages 449 - 454
MCCARRON PAUL A ET AL: "Formulation and characterization of poly(ethylene glycol)-based, 5-aminolevuhnic acid-loaded solid-dosage forms intended for photodynamic and photodiagnostic methodologies in the colorectal region", JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, vol. 26, no. 2, 2007, pages 135 - 142, XP009137976, ISSN: 0731-8898 *
SMART ET AL., J. PHARM. PHARMACOL., vol. 36, 1984, pages 295 - 299
STOUGHTON ET AL., DRUG DPV. IND. PHARM., vol. 9, 1983, pages 725 - 744
WILDING I ET AL: "Development of a new engineering-based capsule for human drug absorption studies", PHARMACEUTICAL SCIENCE AND TECHNOLOGY TODAY 20001101 GB LNKD- DOI:10.1016/S1461-5347(00)00311-4, vol. 3, no. 11, 1 November 2000 (2000-11-01), pages 385 - 392, XP002601529, ISSN: 1461-5347 *
WOODFORD ET AL., J. TOXICOL. CUT. & OCULAR TOXICOLOGY, vol. 5, 1986, pages 167 - 177
YANG S J ET AL: "Application of nanoparticle in photodynamic diagnosis for colorectal cancer", 2006 NSTI NANOTECHNOLOGY CONFERENCE AND TRADE SHOW - NANOTECH 2006 - 9TH ANNUAL MEETING, BOSTON, MAY 7-11, 2006,, 7 May 2006 (2006-05-07), XP007907514, Retrieved from the Internet <URL:http://www.nsti.org/Nanotech2006/showabstract.html?absno=600 ORD - 2006-05-07> *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992954B2 (en) 2010-03-01 2015-03-31 Photocure Asa Compositions comprising a derivative of 5-aminolevulinic acid
EA028064B1 (ru) * 2012-06-25 2017-10-31 Хенниг Арцнаймиттель Гмбх Унд Ко. Кг Лекарственная форма для продленного высвобождения действующих веществ
KR20150041612A (ko) * 2012-06-25 2015-04-16 헨니그 아르쯔나이미텔 게엠베하 운트 코. 카게 활성 물질의 연장된 방출을 위한 약제학적 형태
WO2014001268A1 (de) * 2012-06-25 2014-01-03 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten freisetzung von wirkstoffen
EA035815B1 (ru) * 2012-06-25 2020-08-14 Хенниг Арцнаймиттель Гмбх Унд Ко. Кг Лекарственная форма в форме слоистой таблетки, способ её изготовления и её применение для лечения головокружения
KR102160837B1 (ko) 2012-06-25 2020-09-29 헨니그 아르쯔나이미텔 게엠베하 운트 코. 카게 활성 물질의 연장된 방출을 위한 약제학적 형태
WO2014079972A1 (en) 2012-11-23 2014-05-30 Photocure Asa Device for photodynamic treatment
EP2968128A4 (en) * 2013-03-12 2016-11-16 Applied Biores Inc CHELATING COFFEE FOR IMPROVED DRUG DISPERSION
US9956426B2 (en) 2015-02-26 2018-05-01 Amol Punjabi Upconverting nanoparticles
US11980772B2 (en) 2015-12-17 2024-05-14 Photocure Asa Method of photodynamic therapy (PDT) for bladder cancer
US11235168B2 (en) 2015-12-17 2022-02-01 Photocure Asa Method of photodynamic therapy (PDT) for bladder cancer
US11565123B2 (en) 2015-12-18 2023-01-31 Photocure Asa Device for photodynamic treatment
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
US11633486B2 (en) 2017-04-17 2023-04-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US12186402B2 (en) 2017-04-17 2025-01-07 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Also Published As

Publication number Publication date
US20120134921A1 (en) 2012-05-31
AU2010257752B2 (en) 2015-04-09
ZA201108850B (en) 2013-02-27
RU2011150920A (ru) 2013-07-20
NZ596946A (en) 2014-07-25
EP2440188A1 (en) 2012-04-18
CN102802612A (zh) 2012-11-28
CR20110649A (es) 2012-03-22
RU2527328C2 (ru) 2014-08-27
PE20120858A1 (es) 2012-08-01
JP2012529451A (ja) 2012-11-22
AU2010257752A1 (en) 2012-01-12
CO6480960A2 (es) 2012-07-16
SG176687A1 (en) 2012-01-30
BRPI1011650A2 (pt) 2016-03-22
CA2763837A1 (en) 2010-12-16
CL2011003115A1 (es) 2012-06-22
MX2011013069A (es) 2012-02-01
KR20140014401A (ko) 2014-02-06

Similar Documents

Publication Publication Date Title
AU2010257752B2 (en) Solid compositions comprising 5-aminolevulinic acid
CA2708137C (en) Use of solid pharmaceutical products comprising 5-aminolevulinic acid
EP3042647B1 (en) Semi-solid compositions and pharmaceutical products comprising 5-aminolevulinic acid esters
WO2010072419A2 (en) Enema preparations and their use
US20200009076A1 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EP2585111A1 (en) Hyperosmotic preparations comprising 5 -amino levulinic acid or derivative as photosensitizing agent
AU2014200004B2 (en) Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis
GB2546128A (en) Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
BR112019016091B1 (pt) Unidade de dosagem oral e uso de floroglucinol e trimetilfloroglucinol

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080025607.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10725043

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2763837

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: CR2011-000649

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/013069

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011003115

Country of ref document: CL

Ref document number: 2010257752

Country of ref document: AU

Ref document number: 9591/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 002072-2011

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012514392

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20117030694

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11179486

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2010725043

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011150920

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2010257752

Country of ref document: AU

Date of ref document: 20100611

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13377692

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1011650

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1011650

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111209